Nutritional Ketosis in Heart Failure (INNKA-HF)

A Phase 1, Crossover, Pharmacokinetic Study of Nutritional Ketosis on Exercise Capacity, Metabolic Adaptations, and Myocardial Function in Chronic Ambulatory Heart Failure

Chronic, ambulatory heart failure patients will be given ketone ester dietary supplementation to determine therapeutic efficacy, metabolic adaptation, pharmacokinetics, associated cognitive changes, and safety within this patient cohort in order to establish preliminary data to later conduct a multi-center randomized clinical trial.

Study Overview

• Status: Unknown
• Conditions: Chronic Heart Failure
• Intervention / Treatment: Drug: beta hydroxybutyrate (BHB) ester; Drug: Placebo

Detailed Description

We previously demonstrated a metabolic signature of increased ketone utilization-increased peripheral blood concentration of beta-hydroxybutyrate (BHB) and decreased myocardial concentration of BHB-and markedly decreased acylcarnitine levels in the failing human myocardium procured from lean, non-diabetic patients with advanced heart failure at the time of cardiac transplantation. In this working model of the metabolic adaptations in human heart failure where the mobilization of lipids and ketones are required for an energetically deficient, failing heart it is likely that the development of insulin resistance may be adaptive since increased insulin or insulin signaling would put a brake on the hydrolysis of lipids and hepatic ketogenesis. In parallel with the recent discovery that the failing human heart is reliant on ketones, investigators at Oxford and the NIH have identified a nutritional ketone supplement that reliably increases the serum concentration of BHB in humans.

We hypothesize that the induction of ketosis by exogenous administration of the nutritional ketone monoester will improve myocardial function in heart failure by increasing the energetic substrate available to the myocardium, in essence supporting the energetic deficit of the failing human heart which we have demonstrated to be reliant on ketone bodies for fuel given the limited myocardial oxidation of glucose.

This is a prospective, double-blinded, sequence control crossover trial enrolling NYHA Class II-III ambulatory heart failure patients to receive either ketone mono-ester drink versus placebo for two weeks. Following 2 weeks of therapy, echocardiogram and peak exercise test will be performed. There will be a 1-week "washout" period between phases. Subjects will serve as their own controls for this crossover study, as each will have both baseline testing and testing in the setting of mild nutritional ketosis.

• Study Type: Interventional
• Enrollment (Anticipated): 16
• Phase: Phase 1

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Equal to or greater than 18 years of age
2. Diagnosis of heart failure and be classified as NYHA Class II or III either pre-enrollment or at the time of enrollment
3. Stable medical therapy for at least 1 month prior to enrollment
4. Taking appropriate daily cardiac medications as determined by the principal investigator, who is a heart failure specialist

Exclusion Criteria:

1. Atrial fibrillation
2. Inability to exercise on a supine bicycle.
3. Moderate or greater valvular disease.
4. Hemoglobin <10 g/dL.
5. Daily insulin use
6. Hypertrophic, infiltrative, or inflammatory cardiomyopathy.
7. Pericardial disease.
8. Current angina due to clinically significant obstructive epicardial coronary disease
9. Acute coronary syndrome or coronary intervention within the past 2 months.
10. Primary pulmonary arteriopathy.

11. Known clinically significant lung disease defined as:

    1. Current use of supplemental oxygen, aside from nocturnal O2 for the treatment of obstructive sleep apnea
    2. The use of steroids/antibiotics within the past 6 months for an acute exacerbation of obstructive pulmonary disease
    3. Most proximal pulmonary function test indicating severe obstructive disease, defined as an FEV1<50% predicted in the context of an FEV1/FVC ratio of <0.70 ("Stage III COPD according to GOLD Criteria). (note: only to be used if the subject had PFTs prior to screening)
    4. Most proximal 6-minute walk test during which the subject experienced arterial desaturation (<94%) without a subsequent normal study.
12. Ischemia on stress testing without subsequent revascularization or left heart catheterization showing non-obstructive epicardial coronary disease.
13. Significant liver disease impacting synthetic function or volume control.
14. Uncontrolled hypertension: BP >180/110 at baseline.
15. eGFR <30 mL/min/m2 or Cr >2.5.
16. Alcohol dependence
17. Chronic narcotic use that cannot be interrupted
18. Pregnant or lactating females

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Group A; These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).	Drug: beta hydroxybutyrate (BHB) ester; Ketone supplementation given 3x/day (60mL per dose, or 22g BHB); Other Names: Delta G; Drug: Placebo; Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
ACTIVE_COMPARATOR: Group B; These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2	Drug: beta hydroxybutyrate (BHB) ester; Ketone supplementation given 3x/day (60mL per dose, or 22g BHB); Other Names: Delta G; Drug: Placebo; Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
BHB Concentration in blood	Beta-hydroxybutyrate concentration in blood	1 Year
Minutes at maximum exertion [Exercise Capacity]	Minutes at maximum exertion	1 Year
Left ventricular ejection fraction (%)	Left ventricular ejection fraction, measured by echocardiogram	1 Year
Cardiac output (L/min)	Cardiac output, measured by echocardiogram	1 Year
Left ventricular end diastolic diameter (LVEDD) (cm)	LVEDD, measured by echocardiogram	1 Year
Insulin concentration	Insulin concentration in blood	1 Year
Bicarbonate concentration	Bicarbonate concentration in blood	1 Year

Collaborators and Investigators

• Sponsor: Thomas Jefferson University
• Investigators: Principal Investigator: J. Eduardo Rame, M.D., Thomas Jefferson University

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): June 1, 2020
• Primary Completion (ANTICIPATED): June 1, 2021
• Study Completion (ANTICIPATED): June 1, 2021

Study Registration Dates

• First Submitted: March 10, 2020
• First Submitted That Met QC Criteria: April 28, 2020
• First Posted (ACTUAL): May 1, 2020

Study Record Updates

• Last Update Posted (ACTUAL): May 1, 2020
• Last Update Submitted That Met QC Criteria: April 28, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: diabetes; exercise tolerance; insulin; metabolic; ketosis; bioenergetics; beta-hydroxybutyrate
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Metabolic Diseases; Acid-Base Imbalance; Acidosis; Heart Failure; Ketosis
• Other Study ID Numbers: JT#15471

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No